Clinical trials: Neoadjuvant
LOCALLY ADVANCED UNDIFFERENTIATED CARCINOMA NASOPHARYNGEAL TYPE UCNT
PHASE III TRIAL COMPARING, NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY VERSUS THE SAME NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY ASSOCIATED WITH DAILY HYDROXYUREA IN THE TREATMENT OF LOCALLY ADVANCED UNDIFFERENTIATED CARCINOMA NASOPHARYNGEAL TYPE.
MULTICENTRIC INTERNATIONAL RANDOMIZED PHASE III TRIAL COMPARING, NEOADJUVANT CHEMOTHERAPY (BEC REGIMEN) FOLLOWED BY STANDARD RADIOTHERAPY (70 Gy / 7 WEEKS) VERSUS THE SAME NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD…
- Trial name
- NCT00180973
- Testing
- Hydroxyurea
- Where
- France
- Volunteers
- 520 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Rectal Neoplasm
Validate the Dosimetric Parameters That Correlate With Acute Hematologic Toxicity (HT) in Patients With Rectal Cancer
The purpose of this study is to validate the dosimetric parameters that correlate with acute hematologic toxicity (HT) in patients with rectal cancer treated with neoadjuvant chemoradiotherapy.
- Trial name
- NCT02630056
- Volunteers
- 90 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Breast Cancer
Fulvestrant (FASLODEX™) as a Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer
The purpose of this study is to evaluate fulvestrant in the preliminary stage of breast cancer treatment and assess the relationship between dose, exposure, degree of reduction in tumor markers, and efficacy in postmenopausal…
- Trial name
- NCT00093002
- Testing
- Fulvestrant
- Where
- 31 sites in United States, Austria and 4 more
- Volunteers
- 179 people
- Sponsor
- AstraZeneca
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radical Cystectomy for Locally Advanced Carcinoma (Cancer) of the Urothelium
RATIONALE: Drugs used in chemotherapy, such as ifosfamide, doxorubicin, gemcitabine, and cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00080795
- Testing
- filgrastim, cisplatin, doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- M.D. Anderson Cancer Center
Lung Transplant Rejection
Extracorporeal Photopheresis in Lung Transplant Rejection for Cystic Fibrosis (CF) Patients
Background/Rationale Acute rejection (AR) is common in the first year after lung transplantation. AR has usually been reversible with treatment, but it can trigger chronic rejection that is the leading causes of late morbidity…
- Trial name
- PHORLUCY (NCT03500575)
- Testing
- photopheresis
- Where
- Italy
- Volunteers
- 24 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Ovarian Cancer, Postoperative Complications
Systematic Lymphadenectomy During Interval Debulking Surgery in Advanced Epithelial Ovarian Cancer
The study aims to investigate the prognostic and postoperative complication relevance of lymphadenectomy in advanced epithelial ovarian cancer patients who received neoadjuvant chemotherapy (NACT) followed by interval debulking…
- Conditions
- Ovarian Cancer, Postoperative Complications, Neoadjuvant Therapy, Lymph Node Excision
- Trial name
- NCT06385912
- Testing
- lymphadenectomy
- Where
- China
- Volunteers
- 1,090 people
- Sponsor
- Tongji Hospital
Invasive Breast Cancer
Sentinel Lymph Node Biopsy in Clinically Node-negative Early Breast Cancer Patients After Neoadjuvant Chemotherapy
This is a prospective, single-center, non-randomized, non-controlled observational study.
- Trial name
- NCT03381092
- Where
- China
- Volunteers
- 348 people
- Sponsor
- Peking University
Nasopharyngeal Carcinoma
Target Volume Delineation After NACT in LA-NPCarcinoma Patients Treated With NACT+ CCRT
The gross tumor volumes of the primary site and the neck nodes (GTVnx and GTVnd) could be delineated according to the post-NACT tumor position and receive radical radiation dose, while the tumor disappear after NACT could be…
- Trial name
- NCT03283293
- Testing
- Target Volume Delineation after NACT
- Where
- China
- Volunteers
- 112 people
- Sponsor
- Sun Yat-sen University
Breast Cancer, Sentinel Lymph Node
Impact of a Predictive Model on Sentinel Lymph Node Biopsy in Initially Lymph Node-positive, HER2-positive Breast Cancer
The aim of the study was to develop and validate a nomogram to assess axillary pathological complete response (pCR) in patients with initially lymph node-positive, human epidermal growth factor receptor 2 (HER2)-positive breast…
- Trial name
- NCT06149377
- Testing
- Test cohort
- Where
- China
- Volunteers
- 716 people
- Sponsor
- Fujian Medical University Union Hospital
Localized Osteosarcoma, Metastatic Osteosarcoma
Biomarkers in Predicting Response to Chemotherapy in Samples From Young Patients With Osteosarcoma
This research study is studying biomarkers in predicting response to chemotherapy in samples from young patients with osteosarcoma.
- Conditions
- Localized Osteosarcoma, Metastatic Osteosarcoma, Osteoblastic Osteosarcoma, Recurrent Osteosarcoma
- Trial name
- NCT01374672
- Testing
- laboratory biomarker analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Children's Oncology Group
Inflammatory Breast Cancer, Male Breast Cancer
Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer
This phase II trial studies how well giving sunitinib malate together with paclitaxel, doxorubicin hydrochloride, and cyclophosphamide before surgery works in treating patients with stage IIB-IIIC breast cancer.
- Conditions
- Inflammatory Breast Cancer, Male Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
- Trial name
- NCT00513695
- Testing
- sunitinib malate, paclitaxel, doxorubicin hydrochloride
- Where
- 7 sites in United States
- Volunteers
- 68 people
- Sponsor
- University of Washington
Epithelial Ovarian Cancer, Fallopian Tube Neoplasms
SUROVA - Surgery in Ovarian Cancer, Comparing Primary and Interval Cytoreductive Surgery
An international worldwide retrospective cohort observational study comparing primary cytoreductive surgery with neoadjuvant chemotherapy and interval cytoreductive surgery in patients with carcinoma of the ovary, fallopian…
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Neoplasms, Peritoneal Neoplasms
- Trial name
- SUROVA (NCT06223763)
- Testing
- Cytoreductive surgery, Neoadjuvant chemotherapy, Adjuvant chemotherapy
- Where
- Spain
- Volunteers
- 5,000 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
Stage IIB-III NSCLC, Sleeve Lobectomy
RATS Sleeve Lobectomy After Neo-Chemo-IO for NSCLC
The goal of this multicenter prospective observational study is to learn about the surgical difficulty and outcomes of robotic-assisted sleeve lobectomy in patients with non-small cell lung cancer (NSCLC) after neoadjuvant…
- Conditions
- Stage IIB-III NSCLC, Sleeve Lobectomy, Robotic Surgery, Neoadjuvant Chemoimmunotherapy
- Trial name
- RIDDLE-NSCLC (NCT07541521)
- Testing
- Robot-assisted thoracoscopic surgery (RATS) sleeve lobectomy
- Where
- 10 sites in China, France and 1 more
- Volunteers
- 100 people
- Sponsor
- Shanghai Chest Hospital
Melanoma, Skin
Omitting Therapeutic Lymph Node Dissection in Patients With Melanoma (Stage 3) and Major Pathological Response in the Index Lymph Node
Rationale: The randomized trial NADINA has demonstrated that neoadjuvant treatment with nivolumab with ipilimumab improves event-free survival (EFS) in patients with macroscopic resectable stage III melanoma.
- Trial name
- OMIT (NCT06754904)
- Testing
- Omitting TLND, Index node procedure
- Where
- Netherlands
- Volunteers
- 213 people
- Sponsor
- D.J. (Dirk) Grünhagen
Soft Tissue Sarcoma
Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of High-risk Soft Tissue Sarcoma
This study is a open-lable , single arm，single center, phase II clinical study. Target population is patients with high-risk Soft tissue sarcoma.
- Trial name
- NCT04606108
- Testing
- Camrelizumab in Combination With Neoadjuvant Chemotherapy
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Sun Yat-sen University
Breast Neoplasms
Single-cell RNAseq Breast Cancer
Molecular characterization of persistent tumor cells remaining after NAC and infiltrating immune cells, for example, M2 macrophages, could strongly contribute to identifying targeted therapeutic approaches for this disease.
- Trial name
- SCRBC (NCT05807516)
- Testing
- Single-cell RNA sequencing (scRNAseq), whole-exome sequencing (WES)
- Where
- 2 sites in Italy
- Volunteers
- 20 people
- Sponsor
- Regina Elena Cancer Institute
Tongue Neoplasms, Squamous Cell Carcinoma
Role of Neo-adjuvant Chemotherapy in Tongue Preservation in Locally Advanced Squamous Cell Carcinoma of Oral Tongue
Patients enrolled for the study, who are eligible for NACT, will undergo a pre-treatment workup comprising of Evaluation Under Anesthesia (EUA) for tumor Mapping and tissue biopsy along with a PET-CT scan.
- Conditions
- Tongue Neoplasms, Squamous Cell Carcinoma, Anterior Tongue Squamous Cell Carcinoma
- Trial name
- NCT02985255
- Testing
- Docetaxel, Cisplatin, 5FU
- Where
- India
- Volunteers
- 30 people
- Sponsor
- HealthCare Global Enterprise Ltd.
Breast Cancer
FRAGRANCE Part A Safety: Study to Find a Genetic Signature of de Novo Resistance to Letrozole
Find a genetic signature of de novo resistance to letrozole in adjuvant breast cancer;
- Trial name
- NCT00199134
- Testing
- Letrozole
- Where
- Belgium
- Volunteers
- 49 people
- Sponsor
- Jules Bordet Institute
Ganglioneuroblastoma, Localized Resectable Neuroblastoma
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
This pilot clinical trial studies induction therapy followed by iobenguane I 131 and chemotherapy in treating patients with newly diagnosed high-risk neuroblastoma undergoing stem cell transplant, radiation therapy, and…
- Conditions
- Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma
- Trial name
- NCT01175356
- Testing
- 3-Dimensional Conformal Radiation Therapy, Autologous Hematopoietic Stem Cell Transplantation, Busulfan
- Where
- 25 sites in United States
- Volunteers
- 99 people
- Sponsor
- Children's Oncology Group
ALL, Adult, Philadelphia-Negative ALL
RDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL.
In this study, newly diagnosed non-elderly patients with Philadelphia chromosomal negative (PH-) B-ALL were enrolled and 1:1 randomised into Reduced-intensity chemotherapy followed by Blinatumomab cohort or hyperCVAD cohort as…
- Trial name
- BEAT-ALL-2024 (NCT06250959)
- Testing
- Blinatumomab Injection [Blincyto], Doxorubicin
- Where
- China
- Volunteers
- 124 people
- Sponsor
- Chen Suning